Biotech Assistant
Share useful research with your peers
in · Share on LinkedIn ↗
RESEARCH / LITERATURE

Research Literature

Find research, methods, and reviews across our scientific fields.

One collection · Original publication dates · Authors, journals & DOIs

Protein degradation / PROTAC 5

Duplicate DOIs are merged. This is a selected collection, not an exhaustive bibliography.

Clear filtersExport this page · RIS ↓
Original research
Nature Materials

In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites

Yijia Li; Ting Yang; Xiyue Zhang; Rui Peng; Jifang Gong; Zihan Zhang; Bin Ma; Yu Hou; Yunxuan Liu; Kemeng Chen; Qidong Bai; Yian Fang; Changdi Cao; Jia Hao; Zhiwei Sun; Ziqiong Jiang; Mengying Dong; Chenlong Wei; Zhongtang Li; Qiang Zhang; Lin Shen; Xueqing Wang; Mi Deng; Changsong Qi; Lei Miao

A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.

mRNA / LNPIn Vivo Cell Engineering & Gene EditingProtein degradation / PROTAC
Read guide →Original paper ↗

DOI: 10.1038/s41563-026-02769-2

Reviews & perspectives
Frontiers in Pharmacology

Review assesses the safety limits and translational gaps of MCL-1 degradation strategies

Shuai Liu; Shan Jiang; Mengjiao Zhang; Weixiao Wang; Huiru Peng; Wei Yang

A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.

Protein degradation / PROTAC
Read guide →Original paper ↗

DOI: 10.3389/fphar.2026.2010618

Reviews & perspectives
Journal of Medicinal Chemistry

Perspective examines DCAF16 recruitment beyond CRBN and VHL

Xiaofan Ge; Hua Xiang; Guoshun Luo

A Journal of Medicinal Chemistry perspective examines DCAF16-recruiting degraders, including recruiting motifs, structure–activity relationships, and structural design principles. The original abstract discusses bifunctional and monovalent approaches and highlights movement of programs such as PLX-61639 and AMX-883 toward clinical evaluation. This is a medicinal chemistry synthesis, not a new comparative clinical trial or proof of superiority.

Protein degradation / PROTAC
Read guide →Original paper ↗

DOI: 10.1021/acs.jmedchem.6c02348

Original research
Proceedings of the National Academy of Sciences

Bispecific protein drives dual receptor degradation in mouse eye-disease models

Jialun Zhang; Mingming Du; Lingying Ge; Yuheng Cao; Jiang Jiang; Xue Yin; Guangcun Chen; Qiangbin Wang

A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.

Protein degradation / PROTAC
Read guide →Original paper ↗

DOI: 10.1073/pnas.2613631123

Original research
New England Journal of Medicine

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer

Mario Campone; Michelino De Laurentiis; Komal Jhaveri; Xichun Hu; Sylvain Ladoire; Anne Patsouris; Claudio Zamagni; Jiuwei Cui; Marina Cazzaniga; Timucin Cil; Katarzyna J Jerzak; Christian Fuentes; Tetsuhiro Yoshinami; Alvaro Rodriguez-Lescure; Ahmet Sezer; Andrea Fontana; Valentina Guarneri; Andrea Molckovsky; Marie-Ange Mouret-Reynier; Umut Demirci; Yongqiang Zhang; Olga Valota; Dongrui R Lu; Marcella Martignoni; Janaki Parameswaran; Xin Zhi; Erika P Hamilton

In the randomized phase 3 VERITAC-2 trial, vepdegestrant improved progression-free survival versus fulvestrant in the ESR1-mutated subgroup, but not significantly in the overall population. The trial enrolled 624 patients with previously treated ER-positive, HER2-negative advanced breast cancer. Grade 3 or higher adverse events occurred more often with vepdegestrant.

Protein degradation / PROTAC
Read guide →Original paper ↗

DOI: 10.1056/nejmoa2505725

AI assistant ↗